Literature DB >> 22095154

Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.

Yoshihito Souma1, Toshirou Nishida, Satoshi Serada, Kota Iwahori, Tsuyoshi Takahashi, Minoru Fujimoto, Barry Ripley, Kiyokazu Nakajima, Yasuaki Miyazaki, Masaki Mori, Yuichiro Doki, Yoshiki Sawa, Tetsuji Naka.   

Abstract

Inflammation is a crucial driving force in the development of gastric cancers (GCs). Accordingly, persistent activation of STAT3, a transcription factor pivotal in regulating both inflammation and oncogenesis, is often detected in GC, although its mechanism remains elusive. Suppressor of cytokine signaling-1 (SOCS-1) is a negative regulator of proinflammatory cytokine signaling and SOCS-1 gene methylation is frequently detected in various cancers including GC. However, the significance of SOCS-1 methylation in GC cells remains unexplored. Our study is undertaken to evaluate the role of SOCS-1 in GC cell proliferation and its effect on signaling pathways in GC cells. Among five GC cell lines, SOCS-1 gene was methylated in all cell lines and constitutive STAT3 phosphorylation with elevated endogenous IL-6 production was detected in two cell lines (NUGC-3 and AGS). Unexpectedly, anti-IL-6R antibody inhibited neither cell proliferation nor STAT3 phosphorylation in NUGC-3 and AGS. In contrast, enforced SOCS-1 expression by adenoviral vector (AdSOCS-1) markedly suppressed STAT3 phosphorylation and proliferation of NUGC-3 and AGS cells in vitro. Interestingly, the antiproliferative effect of SOCS-1 was attributable not only to the inhibition of STAT3 but also to that of p38 MAPK activity, and chemical inhibitors of JAK/STAT and p38 MAPK signaling effectively suppressed proliferation of these GC cells. Furthermore, treatment with AdSOCS-1 in vivo significantly suppressed GC proliferation in a xenograft model. These results suggest that SOCS-1 gene methylation is a critical step in the development of GC, and enforced expression of SOCS-1 may represent a novel therapeutic approach for the treatment of GC.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095154     DOI: 10.1002/ijc.27350

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.

Authors:  Takahito Sugase; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Kosuke Hiramatsu; Toshirou Nishida; Seiichi Hirota; Yurina Saito; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Kazuhiro Hanasaki; Tadamitsu Kishimoto; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Gastric Cancer       Date:  2018-04-05       Impact factor: 7.370

2.  A novel therapeutic approach for esophageal squamous cell carcinoma: suppressor of cytokine signaling-1 gene therapy.

Authors:  Chang-Han Chen; Shau-Hsuan Li
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 3.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

4.  Insulin-like growth factor 1 receptor and p38 mitogen-activated protein kinase signals inversely regulate signal transducer and activator of transcription 3 activity to control human dental pulp stem cell quiescence, propagation, and differentiation.

Authors:  Jerome Vandomme; Yasmine Touil; Pauline Ostyn; Cecile Olejnik; Pilar Flamenco; Raja El Machhour; Pascaline Segard; Bernadette Masselot; Yves Bailliez; Pierre Formstecher; Renata Polakowska
Journal:  Stem Cells Dev       Date:  2014-01-17       Impact factor: 3.272

5.  Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells.

Authors:  Moon Kyung Joo; Jong-Jae Park; Hyo Soon Yoo; Beom Jae Lee; Hoon Jai Chun; Sang Woo Lee; Young-Tae Bak
Journal:  Tumour Biol       Date:  2015-10-27

6.  Reduced SOCS1 Expression in Lung Fibroblasts from Patients with IPF Is Not Mediated by Promoter Methylation or Mir155.

Authors:  Cecilia M Prêle; Thomas Iosifidis; Robin J McAnulty; David R Pearce; Bahareh Badrian; Tylah Miles; Sarra E Jamieson; Matthias Ernst; Philip J Thompson; Geoffrey J Laurent; Darryl A Knight; Steven E Mutsaers
Journal:  Biomedicines       Date:  2021-04-30

7.  Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.

Authors:  Rie Natatsuka; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomohiro Ookawara; Toshirou Nishida; Hisashi Hara; Takahiko Nishigaki; Emi Harada; Takashi Murakami; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Tadamitsu Kishimoto; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

Review 8.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

9.  An increase in integrin-linked kinase non-canonically confers NF-κB-mediated growth advantages to gastric cancer cells by activating ERK1/2.

Authors:  Po-Chun Tseng; Chia-Ling Chen; Yan-Shen Shan; Wen-Teng Chang; Hsiao-Sheng Liu; Tse-Ming Hong; Chia-Yuan Hsieh; Sheng-Hsiang Lin; Chiou-Feng Lin
Journal:  Cell Commun Signal       Date:  2014-11-15       Impact factor: 5.712

10.  Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma.

Authors:  Hisashi Hara; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Rie Nakatsuka; Emi Harada; Takahiko Nishigaki; Yusuke Takahashi; Satoshi Nojima; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Eiichi Morii; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Br J Cancer       Date:  2016-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.